Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC

SUZHOU, China, Sept. 29, 2022 /PRNewswire/ — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.